{
    "organizations": [],
    "uuid": "a23215cdaf72118851ca8c86ed884dc0580c5d4e",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/12/business-wire-veracyte-to-host-conference-call-and-webcast-to-discuss-fourth-quarter-and-full-year-2017-financial-results-on-tuesday.html",
    "ord_in_thread": 0,
    "title": "Veracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2017 Financial Results on Tuesday, February 27, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) announced today that it will report its fourth quarter and full-year 2017 financial results after the close of market on Tuesday, February 27, 2018. Following the announcement, Veracyte will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The call may be accessed as follows:\nVeracyte Fourth Quarter and Full-Year 2017 Conference Call, February 27, 2018 at 4:30 p.m. ET Website: http://investor.veracyte.com\nDial-in number (U.S.): (855) 541-0980\nInternational number: (970) 315-0440\nConference ID: 6179798\nThe webcast replay will be available on the company's website approximately two hours following completion of the call and archived on the company's website.\nAbout Veracyte\nVeracyte (NASDAQ: VCYT) is a leading genomic diagnostics company that is providing trustworthy and actionable answers that fundamentally improve patient care when current diagnostic tests are uncertain. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).\nVeracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180212005185/en/\nMedia:\nTracy Morris, 650-380-4413\ntracy.morris@veracyte.com\nor\nInvestors:\nKeith Kennedy, 650-243-6357\nChief Financial Officer\nkeith@veracyte.com\nSource: Veracyte",
    "published": "2018-02-12T16:00:00.000+02:00",
    "crawled": "2018-02-12T17:28:09.043+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "south",
        "san",
        "francisco",
        "business",
        "wire",
        "veracyte",
        "nasdaq",
        "vcyt",
        "announced",
        "today",
        "report",
        "fourth",
        "quarter",
        "financial",
        "result",
        "close",
        "market",
        "tuesday",
        "february",
        "following",
        "announcement",
        "veracyte",
        "host",
        "conference",
        "call",
        "webcast",
        "eastern",
        "time",
        "discus",
        "company",
        "financial",
        "result",
        "provide",
        "general",
        "business",
        "update",
        "call",
        "may",
        "accessed",
        "follows",
        "veracyte",
        "fourth",
        "quarter",
        "conference",
        "call",
        "february",
        "et",
        "website",
        "http",
        "number",
        "international",
        "number",
        "conference",
        "id",
        "webcast",
        "replay",
        "available",
        "company",
        "website",
        "approximately",
        "two",
        "hour",
        "following",
        "completion",
        "call",
        "archived",
        "company",
        "website",
        "veracyte",
        "veracyte",
        "nasdaq",
        "vcyt",
        "leading",
        "genomic",
        "diagnostics",
        "company",
        "providing",
        "trustworthy",
        "actionable",
        "answer",
        "fundamentally",
        "improve",
        "patient",
        "care",
        "current",
        "diagnostic",
        "test",
        "uncertain",
        "company",
        "product",
        "uniquely",
        "combine",
        "genomic",
        "technology",
        "clinical",
        "science",
        "machine",
        "learning",
        "provide",
        "answer",
        "give",
        "physician",
        "patient",
        "clear",
        "path",
        "forward",
        "without",
        "risky",
        "costly",
        "surgery",
        "often",
        "unnecessary",
        "since",
        "founding",
        "veracyte",
        "commercialized",
        "three",
        "genomic",
        "test",
        "transforming",
        "diagnosis",
        "thyroid",
        "cancer",
        "lung",
        "cancer",
        "idiopathic",
        "pulmonary",
        "fibrosis",
        "collectively",
        "target",
        "billion",
        "market",
        "opportunity",
        "veracyte",
        "based",
        "south",
        "san",
        "francisco",
        "california",
        "information",
        "please",
        "visit",
        "follow",
        "company",
        "twitter",
        "veracyte",
        "veracyte",
        "afirma",
        "percepta",
        "envisia",
        "veracyte",
        "logo",
        "afirma",
        "logo",
        "trademark",
        "veracyte",
        "view",
        "source",
        "version",
        "http",
        "medium",
        "tracy",
        "morris",
        "investor",
        "keith",
        "kennedy",
        "chief",
        "financial",
        "officer",
        "keith",
        "source",
        "veracyte"
    ]
}